Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases.
- and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases.
- The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.
- The strategic collaboration will integrate Solid Biosciences’ vector biology, manufacturing capabilities and drug development experience with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics.
- “Our pipeline of programs focused on neuromuscular and cardiac rare disease gives us deep insight into the diverse and complex nature of dilated cardiomyopathy.